11 / 111
R
ev
A
ssoc
M
ed
B
ras
2014; 60(5):399
399
Accreditation
Update on late-onset hypogonadism (loh) or adam: diagnosis
A
tualização
em
hipogonadismo masculino
tardio
(HMT)
ou
D
aem
:
diagnóstico
B
ernardo
WM, M
artits
AM, C
osta
EMF, N
ardi
AC, N
ardozza
J
r
. A, F
aria
G, F
acio
J
r
. FN
http://dx.doi.org/10.1590/1806-9282.60.05.0031. The main signs and symptoms involved in late-
-onset male hypogonadism include the following,
except:
a.
Erectile dysfunction and decreased libido.
b.
Anxiety.
c.
Depression.
d.
Decreased testicular volume.
2. On the main instruments used in the definition
and diagnostic assessment of male aging, we can-
not affirm that:
a.
When analyzing the responses to the ADAM question-
naire, clinically suspected cases of LOH are those in
which the symptoms of sexual dysfunction are present.
b.
The Smith questionnaire is considered a question-
naire to assess the risk of LOH.
c.
It is recommendable for the AMS scale and ADAM
questionnaire to be used as screening instruments.
d.
The use of the three instruments makes the diagno-
sis of HMT through functional and biochemical cri-
teria unnecessary.
3. What is the role of the serum and free testoster-
one (bat) levels in the diagnosis of late-onset hy-
pogonadism?
a.
Free testosterone is a less precise marker of hypog-
onadism.
b.
The result of the total testosterone level does not af-
fect the determination of free testosterone.
c.
TT (total testosterone) would not be the ideal meas-
ure to assess late-onset hypogonadism.
d.
There is a fall in testosterone and BAT levels at 2.3%/
year and 1.1%/year.
4. Tests to be requested before the start of hormone
replacement therapy (art) include the following,
except:
a.
Baseline testosterone measurement.
b.
Lipid evaluation.
c.
Baseline PSA levels.
d.
Evaluation of renal function.
5. How should prostate cancer be monitored?
a.
Ultrasound-guided prostate biopsy.
b.
PSA higher than 4 ng/mL or 3 ng/mL in men with a
high risk of prostate cancer.
c.
An increase in PSA levels higher than 1.4 ng/mL in
any 12 month period during treatment.
d.
Detection of prostatic abnormality during rectal ex-
amination.